Wellreb D 30mg/20mg Capsule SR is a combination medication containing Domperidone 30mg and Rabeprazole 20mg, formulated for the treatment of gastrointestinal disorders associated with acid reflux and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea and vomiting. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The sustained-release formulation ensures prolonged therapeutic action, improving patient compliance by reducing dosing frequency. Wellreb D is indicated for patients experiencing symptomatic GERD with delayed gastric emptying, offering both symptomatic relief and mucosal healing. It should be used under medical supervision, with caution advised in patients with hepatic impairment or those taking medications that may interact with either component. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances. This combination therapy provides a comprehensive approach to managing complex acid-related gastrointestinal conditions.